IN VITRO ANTI-DIABETIC ACTIVITY OF MICROENCAPSULATED AND NON-ENCAPSULATED ASTAXANTHIN
Objective: Diabetes is a long term condition which indicates the high blood pressure. The symptoms indicates, polyuria (frequent urination), they will become increasingly thirsty (polydipsia) and hungry (polyphagia). Many drugs has been discovered for curing diabetes. Recent studies reported that the administration of astaxanthin reduces the blood pressure in the diabetic patient. Astaxanthin is a powerful antioxidant found in wide variety of aquatic living organism which has wide applications in pharmacological studies.
Methods: In vitro antidiabetic study of both encapsulated and non-encapsulated astaxanthin such as DNSA method, starch-iodine color assay method and Î± glycosidase enzymes assay was carried out.
Results: The results of the present study indicated that both encapsulated and non-encapsulated astaxanthin shows higher antidiabetic activity in all the method. Each test samples possess the best activity when compared to standard drug acarbose.
Conclusion: The present study, it is concluded that both non-encapsulated and encapsulated astaxanthin exhibit good antidiabetic activity.
2. IDF Diabetes Atlas. International Diabetes Federation; 2015. Available from: http://www.idf.org/idf-diabetes-atlas-seventh-edition. [Last accessed on 14 Apr 2016]
3. Pontiroli AE, Camisasca R. Additive effect of overweight and type 2 diabetes in the appearance of coronary heart disease but not of stroke: a cross-sectional study. Acta Diabetol 2002;39:83-90.
4. Grundy SM, Bryan Brewer JH, Cleeman JI, Sidney J, Smith C, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
5. Higuera-Ciapara I, FÃ©lix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr 2006;46:185â€“96.
6. Kurashige M, Okimasu E, Inoue M, Utsumi K. Inhibition of oxidative injury of biological membranes by astaxanthin. Physiol Chem Phys Med NMR 1990;22:27â€“38.
7. Ohgami K, Shiratori K, Kotake S, Nishida T, Mizuki N, Yazawa K, et al. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Visual Sci 2003;44:2694â€“701.
8. Uchiyama K, Naito Y, Hasegawa G, Nakamura N, Takahashi J, Yoshikawa T. Astaxanthin protects beta-cells against glucose toxicity in diabetic db/db mice. Red Rep 2002;7:290â€“300.
9. Oâ€™Connor I, Oâ€™Brien N. Modulation of UVA light-induced oxidative stress by beta-carotene, lutein and astaxanthin in cultured fibroblasts. J Dermatol Sci 1998;16:226â€“30.
10. Iwamoto T, Hosoda K, Hirano R, Kurata H, Matsumoto A, Miki W, et al. Inhibition of low-density lipoprotein oxidation by astaxanthin. J Atheroscl Throm 2000;7:216â€“22.
11. Kang JO, Kim SJ, Kim H. Effect of astaxanthin on the hepatotoxicity, lipid peroxidation and antioxidative enzymes in the liver of CCl4-treated rats. Methods Find Exp Clin Pharmacol 2001;23:79â€“84.
12. Aoi W, Naito Y, Sakuma K, Kuchide M, Tokuda H, Maoka T, et al. Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Antioxid Redox Signaling 2003; 5:139â€“44.
13. Leite MF, de Lima A, Massuyama M, Otton R. In vivo astaxanthin treatment partially prevents antioxidant alterations in dental pulp from alloxan-induced diabetic rats. Int Endocrinal J 2010;43:959â€“67.
14. Lin SF, Chen YC, Chen RN, Chen LC, Ho HO, Tsung YH, et al. Improving the stability of astaxanthin by microencapsulation in calcium alginate beads. PloS One 2016;11:1-10.
15. Park SA, Ahn JB, Choi SH, Lee JS, Lee HG. The effects of particle size on the physiochemical properties of optimized astaxanthin-rich Xanthophyllomyces dendrorhous-loaded microparticles. LWT-Food Sci Tech 2014;55:638-44.
16. Krasaekoopt W, Bhandari B, Deeth H. Survival of probiotics encapsulated in chitosan-coated alginate beads in yoghurt from UHT-and conventionally treated milk during storage. Food Sci Technol 2006;39:177-83.
17. Phathanee Thamaket, Patcharin Raviyan. Preparation and physical properties of carotenoids encapsulated in chitosan cross linked triphosphate nanoparticles. Food Appl Biosci J 2015;3:69-84.
18. Yangchao L, Boce Z, Monica W, Liangli Y, Qin W. Preparation and characterization of zein/chitosan complex for encapsulation of alpha tocopherol and Its in vitro controlled release study. Colloids Surf B 2011;85:145-52.
19. Chiu CH, Chang CC, Lin ST, Chyau CC, Peng RY. Improved hepatoprotective effect of liposome-encapsulated astaxanthin in lipopolysaccharide-induced acute hepatotoxicity. Int J Mol Sci 2016;17:1-17.
20. Bhatt UP, Sati SC, Subhash Chandra, Sudhir Kumar, Amit Anthwal, Rajendra Singh, et al. Evaluation of in vivo and in vitro antidiabetic activity of Roylea Cinerea. Int J Pharm Sci Rev Res 2015;32:210-3.
21. Malik CP, Singh MB. Plant Enzymology and Histoenzymology, Kalyani Publishers, New Delhi; 1980. p. 278.
22. Murugesan S, Anand Babu M, Bhuvaneswari S, Kotteswari M, Thennarasan S. In vitro antidiabetic activity of methanolic extracts of selected marine algae. Eur J Pharm Med Res 2015;2:256-60.
23. Narkhede MB, Ajimire PV, Wagh AE, Manoj Mohan, Shivashanmugam AT. In vitro antidiabetic activity of Caesalpina Digyna (R.) methanol root extract. Asian J Plant Sci Res 2011;1:101-6.
24. Murugesan S, Bhuvaneswari S, Sivamurugan V. Evaluation of in vitro antidiabetic activity of red seaweed Portieria Hornemannii (Lyngbye) (Silva) and Spyridia Fusiformis (Wulfen). World J Pharma Sci 2016;4:415-9.
25. Xiao Z, Storms R, Tsang A. A quantitative starch-iodine method for measuring alpha-amylase and glucoamylase activities. Anal Biochem 2006;351:146-8.
26. Ashok Kumar BS, Saleemulla Khan, Gopi Setty Saran, Nandeesh, Manjunath NK. In vitro antidiabetic activity of nisamalaki churna. Sains Malaysiana 2013;42:625-8.
27. Krishnaveni S, Theymoli B, Sadasivam S. Phenol sulfuric acid method. Food Chem 1984;15:229.
28. Andrade-Cetto A, Becerra-Jimenez J, Cardenas-Vazquez R. Alfa-glucosidase-inhibiting activity of some mexican plant used in the treatment of type-2 diabetes. J Ethnopharm 2008;116:27-32.
29. Matsuura H, Asakawa C, Kurimoto M, Mizutani J. Alpha-glucosidase inhibitor from the seeds of balsam pear (Momordica charantia) and the fruit bodies of Grifola frondosa. Biosci Biotech Biochem 2002;66:1576-8.
30. Tietz NW. In: Burtis CA, Ashwood ER. Eds. Tietz Textbook of Clinical Chemistry. Third Ed. Saunders WB; 1999. p. 750â€“78.
31. Kim YM, Wang MH, Rhee HI. A novel alpha-glucosidase inhibitor from pine bark. Carbohydr Res 2004;339:715â€“7.
32. Tonmoy Ghosh, Khushbu Bhayani, Chetan Paliwal, Rahulkumar Maurya, Kaumeel Chokshi, Imran Pancha, et al. Cynobacterial pigments as natural anti-hyperglycemic agents: an in vitro study. Front Marine Sci 2010;3:1-10.
33. Frier BM, Fisher M. Diabetes mellitus. In: Boon NA, Colledge NR, Walker BR, Hunter JAA. Ed. Davidsonâ€™s principle and practice of medicine. 20th ed. (Churchill Livingstone Elsevier: Ediburgh; 2006. p. 805-45.
34. Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwiss 1997;64:536.
35. Davis SN, Granner DK. Insulin, oral hypoglycemic agents and the pharmacology of endocrine pancreas. In: Brunton LL, Lazo JS, Parker KL. Ed. Goodman and Gilmanâ€™s: The pharmacological basis of therapeutics. 11th ed. (McGraw-Hill Medical Publication Division: New York; 2001. p. 1706-7.
36. Conforti F, Statti G, Loizzo MR, Sacchetti G, Poli F, Menichini F. In vitro antioxidant effect and inhibition of alpha-amylase of two varieties of Amaranthus caudatus seeds. Biol Pharm Bull 2005;28:1098-1102.
37. Elumalai Arunkumar, Saravanan Bhuvaneswari, Carani Venkatraman Anuradha. An intervention study in obese mice with astaxanthin, a marine carotenoid-effects on insulin signaling and pro-inflammatory cytokines. Food Func 2012;3:120-6.
38. Bhuvaneswari S, Arunkumar E, Viswanathan P, Anuradha CV. Astaxanthin restricts weight gain, promotes insulin sensitivity and curtails fatty liver disease in mice fed an obesity-promoting diet. Process Biochem 2010;45:1406-14.
39. Hussein G, Nakagawa T, Goto H, Shimada Y, Matsumoto K, Sankawa U, et al. Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sci 2007;80:522-9.
40. Suganya V, Asheeba ST. Microencapsulation of astaxanthin using ionotropic gelation method isolated from three crab varieties. Int J Cur Pharm Res 2015;7:96-9.